EquiReason

EquiReason research coverage

Bristol-Myers Squibb Company BMY

Healthcare · Drug Manufacturers - General

24quarters analysed
12SEC filings read
10segments identified
11institutional managers tracked

Product lines it reports

The product and service lines Bristol-Myers Squibb Company breaks its revenue into.

  • Eliquis
  • Opdivo
  • Orencia
  • Yervoy
  • Pomalyst Imnovid
  • Reblozyl
  • Other Growth Brands
  • Alliance And Other Revenues

Where its revenue is reported

The geographies Bristol-Myers Squibb Company reports revenue for. How much comes from each is in the product.

  • United States
  • Other Region

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements25
  • Quarterly metric series12
  • Business segments10
  • SEC filings12
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks6
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Margin series2
  • Cash flow series24
  • Earnings series24
  • Per-share series2
  • Operating cash flow series24
  • Guidance changesnot found

This page says how much of Bristol-Myers Squibb Company we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open BMY in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Bristol-Myers Squibb Company (BMY) — research coverage | EquiReason